You are here: Industry Insights > Trials

News List

Lead Pharma Announces Start of Phase I Clinical Trials with SAR441169 Candidate Treatment for Psoriasis b3cnewswire
April 17, 2019
Sanofi, Lead Pharma’s collaborative partner in the development of SAR441169...
Some research may be encouraging ineffective prescriptions worldpharmanews
November 28, 2018
A new paper published by McGill University researchers in JAMA Internal Medicine suggests that some clinical trials may promote the use of ineffective and costly treatments.
Trials show benefit of ‘on demand’ use of AZ’ asthma inhaler pharmatimes
May 24, 2018
The trials tested the inhaler in place of current reliever therapy, a short-acting beta2-agonist (SABA), also taken as needed, and as an alternative to regular maintenance controller therapy (twice-daily budesonide, an inhaled corticosteroid, ICS) plus SA
Artificial Intelligence is the Buzz in Clinical Trials biospace
April 27, 2018
At the World Medical Innovation Forum held in Boston this week, panelists focused on the use of artificial intelligence in healthcare.
Accelerating New Clinical Trials and Treatments for Kidney Disease biospace
March 19, 2018
Today, the National Kidney Foundation (NKF) has reached a scientific seminar with the Food and Drug Administration (FDA) and the European Medicines Agency (EMA)
AMO Pharma Sees Positive Results in Phase II Trials biospace
March 19, 2018
AMO Pharma reported that patients treated with its Phase II neuromuscular treatment for onset myotonic dystrophy type 1 experienced clinical benefits
Investors Elated as Vertex Picks Two Top CF Triple Combos for Phase III Trials biospace
February 02, 2018
Vertex is keeping its promise of advancing triple combination treatments for patients with cystic fibrosis and investors are happy.
Aptar Pharma & Kali Care to develop medication monitoring tech for trials europeanpharmaceuticalreview
May 08, 2017
Aptar Pharma and Kali Care have entered into a partnership in order to address the challenge of monitoring adherence in ophthalmic clinical trials.
AbbVie’s PARP inhibitor fails in PhIII trials pharmatimes
April 21, 2017
AbbVie’s experimental PARP inhibitor veliparib has failed to meet key targets in two late-stage studies testing its potential in lung and breast cancer.

Previous page 1 2 Next page